ARVN News and Press, Arvinas Inc. From 09/04/20

NEW HAVEN, Conn., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a firesid...

ESSA Pharma Inc. (NASDAQ: EPIX ) [TSX-V: EPI] is a Canadian/U.S. clinical-stage pharmaceutical company which recently began Phase 1 clinical trials for its lead drug EPI-7386, a novel treatment for men with castration-resistant prostate cancer ("CRPC") where the cancer is progressing despi...

Quick Take Kymera Therapeutics (KYMR) intends to raise $125 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is advancing treatment candidates for skin and immune system conditions. KYMR is still some time away from beginn...

NEW HAVEN, Conn., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ron Peck, M.D., Chief Medical Officer, will participate in a fireside chat ...

Arvinas (NASDAQ: ARVN ) : Q2 GAAP EPS of -$0.65 misses by $0.06 . More news on: Arvinas, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

NEW HAVEN, Conn., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today reported financial results for the second quarter ended June 30, 2020 and provided a corpor...

Quick Take Nurix Therapeutics ( NRIX ) intends to raise $150 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing drug candidates to treat various cancers. NRIX has significant collaboration partners and a top ti...

Quick Take Nurix Therapeutics ( NRIX ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. The company is developing small molecule-based treatments for blood cancers and immune system conditions. NRIX is a promising biopharma with...

NEW HAVEN, Conn., June 29, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Wendy Dixon, Ph.D., has joined its Board of Directors. Dr. Dixon is a well-respe...

NEW HAVEN, Conn., June 17, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside...